2025’s Top Clinical Trials: Closing a Transformative Year in Medicine
2025 was not a year of merely “positive” trials. It was a year defined by effect sizes, first-line shifts, and disease-modifying signals that are already changing real clinical decision-making. Across oncology, cardiometabolic disease, liver and rare disorders, several late-stage readouts stood out not because they met endpoints, but because they reset expectations — introducing new standards of care, validating new platforms, or delivering benefits where progress had stalled for decades.
Below are the trials we would place in the truly remarkable category — the studies that signaled genuine momentum in drug development and clinical impact.
AstraZeneca / Daiichi Sankyo — Enhertu Redefines First-Line HER2+ Metastatic Breast Cancer Care
Enhertu (trastuzumab deruxtecan), an antibody–drug conjugate, became the first ADC approved for first-line treatment of HER2-positive metastatic breast cancer after delivering a marked improvement in progression-free survival versus the long-standing THP standard in the Phase III DESTINY-Breast09 trial.
Why this trial matters:
• First ADC to move into the 1L HER2+ metastatic setting
• Breaks a decade-long treatment paradigm in first-line breast cancer care
• Confirms ADCs as frontline platforms, not just late-line salvage therapies
Roche — Giredestrant Delivers the First Phase III Win for an Oral SERD in Early Breast Cancer
Roche’s oral SERD giredestrant reduced the risk of invasive disease recurrence versus standard endocrine therapy in the Phase III lidERA trial in ER-positive, HER2-negative early breast cancer, marking the first major advance in adjuvant endocrine therapy in decades.
Why this trial matters:
• First oral SERD to succeed in Phase III in early breast cancer
• Signals a potential new adjuvant standard of care
• Advances endocrine therapy beyond legacy agents
Johnson & Johnson — Tecvayli + Darzalex Faspro Shows Unprecedented Phase III Success in Relapsed/Refractory Multiple Myeloma
The Phase III MajesTEC-3 trial demonstrated that the combination of Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab SC) significantly improved progression-free survival and overall survival versus standard regimens in patients with relapsed/refractory multiple myeloma as early as second-line, with an ~83% reduction in disease progression or death at almost three years follow-up.
Why this trial matters:
• First bispecific + CD38 combo to show superior PFS and OS in Phase III in RRMM
• Potential new standard of care as early as second-line
• Demonstrates deep responses, high MRD-negativity, and durable outcomes
First-line Strategies in BRAF V600E-Mutant mCRC: Real-World Evidence Signals Treatment Priorities
In a real-world retrospective cohort of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), frontline chemotherapy plus anti-VEGF therapy was associated with the longest survival outcomes, while BRAF-targeted strategies showed promising response rates, emphasizing the need for tailored therapy and prospective validation.
Why this trial matters:
• Provides real-world evidence on first-line regimens in a poor-prognosis mCRC subtype
• Highlights superior survival with chemo + anti-VEGF versus chemo alone or targeted therapy • Reinforces the importance of personalized treatment strategies and further trials
Eli Lilly — Retatrutide Delivers Unprecedented Weight Loss in Phase III TRIUMPH-4 Trial
Eli Lilly’s investigational triple-agonist retatrutide produced an average ~28.7% body-weight reduction (≈71.2 lbs) at 68 weeks in the Phase III TRIUMPH-4 obesity trial, along with meaningful knee osteoarthritis pain relief, marking one of the strongest weight-loss results reported in late-stage obesity research.
Why this trial matters:
• First triple hormone receptor agonist showing major Phase III weight-loss efficacy
• Delivers weight-loss outcomes far beyond many current therapies
• Suggests a potential new metabolic and obesity care benchmark
Semaglutide Shows Consistent Liver Benefits in MASH
In the Phase III ESSENCE study, once-weekly semaglutide 2.4 mg significantly increased rates of steatohepatitis resolution and fibrosis improvement on liver biopsy in adults with metabolic dysfunction-associated steatohepatitis (MASH), compared with placebo.
Why this trial matters:
• First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH
• Demonstrates semaglutide’s impact beyond weight loss to disease-modifying liver effects
• Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need
Ianalumab Meets Endpoints in Phase III Sjögren’s Disease Trials (NEPTUNUS-1 & 2)
Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjögren’s disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder.
Why this trial matters:
• First global Phase III success in a disease with no approved targeted therapy
• Could change management of systemic symptoms and glandular dysfunction
Gene Therapy Phase III in Epidermolysis Bullosa Shows Healing Benefit
A Phase III gene therapy trial for epidermolysis bullosa (EB) demonstrated significantly better wound healing, less pain, and reduced itching compared with standard care, and the therapy earned FDA approval in 2025 — a major advance for this previously untreatable genetic skin disorder.
Why this trial matters:
• First effective gene therapy for EB
• Meaningfully improves quality of life and patient outcomes
Drug Approvals as a Signal: 2025 Showed Real Late-Stage Productivity
The FDA’s 2025 novel drug approvals, alongside pivotal trial–driven cancer approvals, point to real late-stage productivity rather than incremental gains. Many approvals reflected new mechanisms or first-in-class advances, signaling a meaningful shift in clinical impact and regulatory momentum.
Key Takeaways — What Truly Defined Clinical Research in 2025
- First-linemattered.
Several of the most important advances moved effective therapies into earlier lines of treatment, reshaping care pathways rather than adding incremental options. - Platforms matured.
ADCs, bispecific antibodies, oral SERDs, triple agonists, GLP-1–based therapies, and gene therapies all delivered Phase III–level validation, confirming these are no longer experimental bets. - Metabolic drugs expanded beyond weight and glucose.
Obesity and GLP-1–based therapies showed disease-modifying potential in heart failure, liver disease, and osteoarthritis — broadening their clinical relevance. - Rare and historically neglected diseases finally saw progress.
Sjögren’s disease and epidermolysis bullosa moved from symptomatic management toward targeted, effective therapies. - Regulatory output reflected real innovation.
FDA approvals in 2025 increasingly aligned with pivotal, practice-changing data — signaling genuine late-stage productivity rather than volume-driven progress.
Future Horizons
Taken together, these trials show that 2025 was not defined by marginal gains or isolated wins. It was a year where late-stage research translated into real shifts in clinical thinking — moving powerful platforms earlier in treatment, expanding metabolic drugs into new disease areas, and finally delivering options for conditions long considered underserved or untreatable.
What stands out is not just that these studies met their endpoints, but that many of them changed the question being asked — from “does it work?” to “how fast should this become standard?” This level of impact signals a healthier, more productive late-stage pipeline and a clearer connection between innovation and patient benefit.
At Cromos Pharma, we work alongside sponsors navigating exactly this moment — helping translate late-stage clinical success into well-executed programs that bring meaningful therapies to patients efficiently and responsibly.
As these therapies move from trials into everyday practice, which of these breakthroughs do you believe will have the most lasting impact on how medicine is practiced?
